Brean Capital raised its price target on Salix following Q4 results. The firm is citing upcoming catalysts including a PDUFA date for its drug candidate for acute attacks of angioedema and its acquisition of the worldwide rights to Red Hill's drug formulation for bowel preparation. Shares are Buy rated.
- Health Care Industry
- Investment & Company Information